McNeil

Consumer & Specialty Pharmaceuticals

January 3, 2006

Dear Health Care Provider:

Over the past 12 months, supply constraints have impeded the production of PANCREASE® (pancrelipase) capsules, which have led to an inability to maintain an adequate supply of the product for you and your patients.

Even though an operations team has been working to resolve the problem since the first occurrence, no resolution has been found. Therefore, McNeil Consumer & Specialty Pharmaceuticals has made the difficult decision to cease sales and marketing of PANCREASE capsules, effective January 27, 2006.

PANCREASE® MT (pancrelipase) capsules are manufactured at a different location and have not been affected by supply constraints. They will continue to be widely available for patients with cystic fibrosis and others with pancreatic insufficiency. McNeil Consumer & Specialty Pharmaceuticals remains committed to PANCREASE MT and patients with cystic fibrosis. In fact, we are currently conducting a clinical trial in infants in preparation for filing a new drug application (NDA) for PANCREASE MT.

PANCREASE MT also has a wide range of strengths (MT4, MT10, MT16, and MT20).

Should you require any assistance in converting patients from PANCREASE to PANCREASE MT, please do not hesitate to contact us at 1-888-440-7903 and press **4**. We are here to offer any assistance you need.

Sincerely,

Steven A. Silber, MD
Vice President – Drug Development and Safety

PANCREASE (pancrelipase) capsules and PANCREASE MT (pancrelipase) capsules are indicated for the treatment of steatorrhea secondary to pancreatic insufficiency such as cystic fibrosis or chronic alcoholic pancreatitis.

PANCREASE and PANCREASE MT capsules are contraindicated in patients known to be hypersensitive to pork protein or any other component of these products.

Cases of fibrotic strictures in the colon have been reported primarily in cystic fibrosis patients with the use of enzyme supplements, generally at doses above the recommended range.

Any change in pancreatic enzyme replacement therapy should be made cautiously and only under medical supervision.

To protect the enteric coating, microtablets and microspheres should not be crushed or chewed. Proteolytic enzymes present in pancrelipase, when retained in the mouth, may begin to digest the mucous membranes and cause ulcerations.

With PANCREASE® (pancrelipase) and PANCREASE® MT (pancrelipase), the most frequently reported adverse events were primarily gastrointestinal in nature and included abdominal pain, constipation, diarrhea, flatulence, intestinal obstruction, intestinal stenosis, pain, vomiting, and weight decrease. Also reported were melena, perianal irritation, and rash.

Please see accompanying full prescribing information.

 [code] December 2005